Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Liabilities (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Total Liabilities data on record, last reported at $528.1 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 18.65% year-over-year to $528.1 million; the TTM value through Dec 2025 reached $528.1 million, up 18.65%, while the annual FY2025 figure was $528.1 million, 18.65% up from the prior year.
  • Total Liabilities reached $528.1 million in Q4 2025 per MIRM's latest filing, up from $493.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $528.1 million in Q4 2025 and bottomed at $88.4 million in Q1 2021.
  • Average Total Liabilities over 5 years is $318.6 million, with a median of $373.3 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 727.26% in 2021, then grew 9.01% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $174.4 million in 2021, then grew by 20.88% to $210.9 million in 2022, then surged by 88.72% to $398.0 million in 2023, then increased by 11.85% to $445.1 million in 2024, then grew by 18.65% to $528.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $528.1 million in Q4 2025, $493.1 million in Q3 2025, and $470.7 million in Q2 2025.